Insulin LY2605541 tops glargine for glycemic control in T1DM

Insulin LY2605541 tops glargine for glycemic control in T1DM
For patients with type 1 diabetes, the novel, long-acting basal insulin LY2605541 yields greater improvement in glycemic control compared with insulin glargine, according to a study published online Nov. 27 in Diabetes Care.

(HealthDay)—For patients with type 1 diabetes, the novel, long-acting basal insulin LY2605541 yields greater improvement in glycemic control compared with insulin glargine, according to a study published online Nov. 27 in Diabetes Care.

Julio Rosenstock, M.D., of the Dallas Diabetes and Endocrine Center, and colleagues conducted a randomized, phase 2, open-label, crossover study involving 137 patients with type 1 diabetes who received once-daily (LY2605541 or glargine) plus mealtime insulin for eight weeks.

Compared with , the researchers found that LY2605541 met non-inferiority and superiority criteria and correlated with a significant reduction in the mean (least squares mean difference, −9.9 mg/dL). Significant improvements were also noted in fasting blood glucose variability and glycated hemoglobin with LY2605541 versus insulin glargine. There was a decrease in the mealtime insulin dose and in mean weight with LY2605541, and an increase in both with insulin glargine. The rate of nocturnal hypoglycemia was significantly lower with LY2605541, while the incidence of total hypoglycemia was significantly higher. LY2605541 was also associated with more gastrointestinal-related adverse events than insulin glargine (15 versus 4 percent).

"In conclusion, LY2605541 basal for patients with type 1 diabetes has the potential to improve glycemic control, reduce weight, glucose variability, and nocturnal hypoglycemia, and lower prandial insulin requirements," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Eli Lilly, which funded the study.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Experimental insulin drug prevents low blood sugar

Jun 25, 2012

An experimental insulin drug prevented low blood sugar among diabetic patients more often than a popular drug on the market, a new study finds. The results will be presented at The Endocrine Society's 94th Annual Meeting ...

Recommended for you

Study explores effects of metformin in obese children

Dec 18, 2014

(HealthDay)—For obese hyperinsulinemic children, metformin seems to decrease perceived hunger and increase perceived fullness, according to a study published online Dec. 8 in Diabetes, Obesity and Metabolism.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.